These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35165250)

  • 1. Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT).
    Zielińska K; Kukulski L; Wróbel M; Przybyłowski P; Rokicka D; Strojek K
    Ann Transplant; 2022 Feb; 27():e933420. PubMed ID: 35165250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of cardiac allograft vasculopathy: Importance of the International Society for Heart and Lung Transplantation angiographic grading scale.
    Van Keer JM; Van Aelst LNL; Rega F; Droogne W; Voros G; Meyns B; Vanhaecke J; Emonds MP; Janssens S; Naesens M; Van Cleemput J
    J Heart Lung Transplant; 2019 Nov; 38(11):1189-1196. PubMed ID: 31543298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of Cardiac Allograft Vasculopathy by PCI: Quantification and Correlation With Outcome After Heart Transplantation.
    Orban M; Kuehl A; Pechmajou L; Müller C; Sfeir M; Brunner S; Braun D; Hausleiter J; Bories MC; Martin AC; Ulrich S; Dalla Pozza R; Mehilli J; Jouven X; Hagl C; Karam N; Massberg S
    J Card Fail; 2024 Oct; 30(10):1222-1230. PubMed ID: 39389730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cardiac allograft vasculopathy in heart and heart-lung transplantations: a 15-year retrospective study.
    Guihaire J; Mercier O; Flécher E; Aymami M; Fattal S; Chabanne C; Leroy Ladurie F; Lelong B; Cerrina J; Langanay T; Mussot S; Fabre D; De Latour B; Corbineau H; Verhoye JP; Dartevelle P; Leguerrier A; Fadel E
    J Heart Lung Transplant; 2014 Jun; 33(6):636-43. PubMed ID: 24630860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
    Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
    JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vessel Fractional Flow Reserve and Graft Vasculopathy in Heart Transplant Recipients.
    Nagumo S; Gallinoro E; Candreva A; Mizukami T; Monizzi G; Kodeboina M; Verstreken S; Dierckx R; Heggermont W; Bartunek J; Goethals M; Buytaert D; De Bruyne B; Sonck J; Collet C; Vanderheyden M
    J Interv Cardiol; 2020; 2020():9835151. PubMed ID: 32733172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early aspirin use and the development of cardiac allograft vasculopathy in pediatric heart transplant recipients: A pediatric heart transplant society analysis.
    D'Addese L; Cantor RS; Koehl D; Reardon L; Ameduri R; Bock M; Morrison A; White S; Wisotzkey B; Kirklin JK; Godown J
    J Heart Lung Transplant; 2023 Jan; 42(1):115-123. PubMed ID: 36328858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of longitudinal myocardial deformation by 2-dimensional speckle-tracking echocardiography in heart transplant recipients: relation to coronary allograft vasculopathy.
    Clemmensen TS; Løgstrup BB; Eiskjær H; Poulsen SH
    J Heart Lung Transplant; 2015 Feb; 34(2):195-203. PubMed ID: 25108908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of arrhythmia and silent ischemia in heart transplant patients with cardiac allograft vasculopathy.
    Berg K; Bjerre KP; Clemmensen TS; Løgstrup BB; Mølgaard H; Poulsen SH; Eiskjær H
    Scand Cardiovasc J; 2021 Oct; 55(5):300-307. PubMed ID: 34313167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation.
    Delgado JF; Reyne AG; de Dios S; López-Medrano F; Jurado A; Juan RS; Ruiz-Cano MJ; Dolores Folgueira M; Gómez-Sánchez MÁ; Aguado JM; Lumbreras C
    J Heart Lung Transplant; 2015 Aug; 34(8):1112-9. PubMed ID: 25940077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravascular ultrasound-guided selection for early noninvasive cardiac allograft vasculopathy screening in heart transplant recipients.
    Nelson LM; Rossing K; Ihlemann N; Boesgaard S; Engstrøm T; Gustafsson F
    Clin Transplant; 2020 Dec; 34(12):e14124. PubMed ID: 33068292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High sensitivity troponin I as a biomarker for cardiac allograft vasculopathy: Evaluation of diagnostic potential and clinical utility.
    Patel K; Yadalam A; DeStefano R; Desai S; Almuwaqqat Z; Ko YA; Alras Z; Martini MA; Ejaz K; Alvi Z; Varounis C; Murtagh G; Gupta D; Book W; Quyyumi AA
    Clin Transplant; 2024 Jan; 38(1):e15168. PubMed ID: 37882497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy.
    Bjerre KP; Clemmensen TS; Berg K; Poulsen SH; Hvas AM; Grove EL; Løgstrup BB; Jakobsen L; Thim T; Kristensen SD; Eiskjær H
    J Heart Lung Transplant; 2020 Apr; 39(4):371-378. PubMed ID: 32067865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.
    Johansson I; Andersson R; Friman V; Selimovic N; Hanzen L; Nasic S; Nyström U; Sigurdardottir V
    BMC Infect Dis; 2015 Dec; 15():582. PubMed ID: 26703239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diminished impact of cytomegalovirus infection on graft vasculopathy development in the antiviral prophylaxis era - a retrospective study.
    Goekler J; Zuckermann A; Kaider A; Angleitner P; Osorio-Jaramillo E; Moayedifar R; Uyanik-Uenal K; Kainz FM; Masetti M; Laufer G; Aliabadi-Zuckermann AZ
    Transpl Int; 2018 Aug; 31(8):909-916. PubMed ID: 29577455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
    Kreienbaum H; Stiller B; Kubicki R; Bobrowski A; Kroll J; Fleck T
    Pediatr Transplant; 2024 Mar; 28(2):e14698. PubMed ID: 38433342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Lipoprotein A Levels and Development of Moderate or Severe Cardiac Allograft Vasculopathy in Patients with Heart Transplants.
    González-Quijano M; Grande-Trillo A; Esteve-Ruiz I; Aranda-Dios A; Sobrino-Márquez JM; Rangel-Sousa D
    Transplant Proc; 2023 Dec; 55(10):2295-2298. PubMed ID: 37914618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cardiac allograft vasculopathy incidence between simultaneous multiorgan and isolated heart transplant recipients in the United States.
    Shahandeh N; Kim JS; Klomhaus AM; Tehrani DM; Hsu JJ; Nsair A; Khush KK; Fearon WF; Parikh RV
    J Heart Lung Transplant; 2024 Oct; 43(10):1737-1746. PubMed ID: 38950666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative 3D Analysis of Coronary Wall Morphology in Heart Transplant Patients: OCT-Assessed Cardiac Allograft Vasculopathy Progression.
    Chen Z; Pazdernik M; Zhang H; Wahle A; Guo Z; Bedanova H; Kautzner J; Melenovsky V; Kovarnik T; Sonka M
    Med Image Anal; 2018 Dec; 50():95-105. PubMed ID: 30253306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy.
    Arora S; Andreassen A; Simonsen S; Gude E; Dahl C; Skaardal R; Hoel I; Geiran O; Gullestad L
    Transplantation; 2007 Jul; 84(2):149-54. PubMed ID: 17667805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.